The PI3K/AKT pathway is known to control the oncogenic addiction observed in EGFR‐mutated lung cancer, and its activation has been shown to be a crucial event in the resistance to targeted therapies (Obenauf et al, 2015). The gene discussed is EGFR; the disease is lung carcinoma.